Conduct of Activities. The Organization shall carry out all activities in relation to which it uses the Contribution in a professional manner using all due skill, care and diligence, and in conformity with the Applicable Laws.
Conduct of Activities. The Lessee must conduct, and agrees to conduct, all activities in the leased area and project easement(s) in accordance with an approved SAP or COP, and with all applicable laws and regulations. The Lessee further agrees that no activities authorized by this lease will be carried out in a manner that:
(a) could unreasonably interfere with or endanger activities or operations carried out under any lease or grant issued or maintained pursuant to the Act, or under any other license or approval from any Federal agency;
(b) could cause any undue harm or damage to the environment;
(c) could create hazardous or unsafe conditions; or
(d) could adversely affect sites, structures, or objects of historical, cultural, or archaeological significance, without notice to and direction from the Lessor on how to proceed.
Conduct of Activities. Each Party shall conduct those activities allocated to such Party under the Operating Plan/Budget in compliance in all material respects with all applicable laws, rules and regulations and in accordance with good scientific and clinical practices, applicable under the laws and regulations of the country in which such activities are conducted.
Conduct of Activities. (a) In the performance of its obligations under this Agreement, it will comply, and will cause its and its Affiliates’ employees and contractors to comply, with all Applicable Laws and will obtain and maintain all licenses, permits, approvals and other authorizations applicable to it in order to enable it to perform its respective obligations hereunder.
(b) It (i) will ensure that its personnel receive appropriate training on the Anti-Corruption Laws, (ii) will provide, at the other Party’s request, a certification in a form reasonably satisfactory to such other Party, as to its compliance with the foregoing clause (i), and (iii) agrees, on behalf of itself, its Affiliates, and its and their officers, directors, employees, agents, representatives, consultants, and (sub)contractors (together with such Party, the “Party Representatives”) that, in connection with the performance of its obligations hereunder or the Exploitation of the Licensed Compounds or the Licensed Products, the Party Representatives will comply with Jazz’s anti-corruption policy as set forth at xxx.xxxxxxxxxxxxxxxxxxx.xxx and will not, directly or indirectly, solicit, receive or agree to accept any payment of money or anything else of value in violation of Anti-Corruption Laws or pay, offer or promise to pay, or authorize the payment of any money, or give, offer or promise to give, or authorize the giving of anything else of value, to:
i. any Government Official in order to influence official action;
ii. any Government Official (A) to influence such Person to act in breach of a duty of good faith, impartiality or trust (“Acting Improperly”), (B) to reward such Person for Acting Improperly, or (C) where such Person would be Acting Improperly by receiving the money or other thing of value;
iii. any Person while knowing or having reason to believe that all or any portion of the money or other thing of value will be paid, offered, promised or given to, or will otherwise benefit, a Government Official in order to influence official action for or against either Party in connection with the matters that are the subject of this Agreement; or
iv. any other Person to secure an improper advantage. It is the intent of the Parties that no payments or transfer of value will be made which have the purpose or effect of public or commercial bribery, acceptance of or acquiescence in extortion, kickbacks, or other unlawful or improper means of obtaining or retaining business. This clause will not, however, ...
Conduct of Activities. The awarding of the scholarship covered by this Agreement does not give rise to employment relationships, with the University or the Company either, and does not give rise to rights regarding access to academic positions. The activities carried out at the Company premises will be implemented to the extent permitted by the University PhD Programmes Regulation. The subject responsible for employer’s obligations, as provided for by the Legislative Decree 81/2008 and subsequent amendments and integrations, is the University. The PhD scholarship holder is required to comply with the regulations and safety provisions into force at the premises where the doctoral activities are carried out, pursuant to the Legislative Decree no. 81/2008 and subsequent amendments and integrations, in particular the obligations provided for in Art. 20 of the aforementioned Legislative Decree, as well as the indications provided by the heads of the host structure.
Conduct of Activities. Unless the Parties execute a Co-Promotion Agreement pursuant to Section 5.4 below, Xanodyne shall carry out, at its expense, all marketing, promotion and commercialization of the XenoPort Products in the Territory consistent with the then-current Commercialization Plan and the provisions of this Agreement.
Conduct of Activities. Xanodyne shall conduct the activities under the Development Plan in compliance in all material respects with all applicable laws, rules and regulations and in accordance with good scientific and clinical practices, applicable under the laws and regulations within the portion of the Territory in which such activities are conducted.
Conduct of Activities. (a) From and after the Effective Date, OST shall use Commercially Reasonable Efforts to pursue clinical Development, Regulatory Approvals and commercialization of the Licensed Products in the Field, in each case in accordance with the applicable R&D Plan. Within thirty (30) days following a written request from Advaxis (at a frequency of no more than semi-annually until completion of the COG Study and annually thereafter), OST shall furnish to Advaxis a written report, describing in reasonable detail, OST’s activities to Develop, manufacture and commercialize the Licensed Products, including such activities identified in the OST Operational Plan.
(b) From and after the Effective Date, OST shall have the sole right and responsibility to conduct regulatory activities (including, without limitation, Regulatory Filings and Regulatory Approvals) for each Licensed Product in the Field.
(c) In performing all activities hereunder, OST shall (and shall use Commercially Reasonable Efforts to cause its Affiliates and Sublicensees, as applicable, to agree to) use relevant facilities and equipment in a good scientific manner and in compliance with applicable scientific standards, laboratory practices and legal and regulatory requirements, and retain adequately trained personnel and engage and control adequately qualified internal or external personnel and collect and Develop all relevant Know-How for the Research, Development and commercialization of Licensed Products in the Field.
(d) OST (and its Affiliates) shall perform its activities with respect to Licensed Products in the Field in the Territory in good scientific manner and in compliance with all requirements of applicable laws, rules and regulations, including (as applicable): the U.S. Federal Food, Drug and Cosmetic Act, as amended (FFDCA), the U.S. Public Health Service Act (PHSA), the rules governing medicinal products in the European Union and further national legislation, regulatory provisions regarding protection of animal or human subjects, GCP, GLP, GMP, IND regulations, and any conditions imposed by a Regulatory Authority, and comparable statutes and regulatory requirements in other jurisdictions. OST shall use Commercially Reasonable Efforts to cause its Sublicensees to agree in writing to perform their activities with respect to Licensed Product in accordance with this paragraph.
(e) Notwithstanding any other provision herein, Advaxis will have the right to review and approve or reject the protocols ...
Conduct of Activities. As to all matters contained in this Agreement, each Party shall conduct the activities allocated to it in compliance in all material respects with all Applicable Laws and in accordance with good scientific, clinical and manufacturing practices and applicable industry ethical codes, applicable under the laws and regulations of the country in which such activities are conducted. Each Party represents, warrants and covenants to the other Party as of the Effective Date that:
(a) it is familiar with the provisions and restrictions contained in the OECD Convention and FCPA and it has adopted and maintains an FCPA policy;
(b) In the performance of its obligations under this Agreement, it shall comply and shall cause its and its Affiliates’ employees and contractors to comply with all Applicable Laws, and shall obtain and maintain all licenses, permits, approvals and other authorizations applicable to it in order to enable it to perform its respective obligations hereunder.
(c) its and its Affiliates’ employees and contractors shall not, in connection with the performance of their respective obligations under this Agreement, directly or indirectly through Third Parties, pay, promise or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of anything of value to a Public Official or Entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including either Party (it being understood that such Party, and to its knowledge, its and its Affiliates’ employees and contractors, has not directly or indirectly promised, offered or provided any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift or hospitality or other illegal or unethical benefit to a Public Official or Entity or any other person in connection with the performance of such Party’s obligations under this Agreement, and shall not, directly or indirectly, engage in any of the foregoing).
Conduct of Activities. Each Party shall use Reasonably Diligent Efforts to conduct Development of the Product in a manner consistent with the following: (i) in the case of Mundipharma, not materially adversely impacting Allos’ or its Affiliates’ or Third Party partner’s Development or Commercialization efforts for the Product in the Field in the Allos Territory; and (ii) in the case of Allos, not materially adversely impacting Mundipharma’s or its Affiliates’ or Sublicensees’ Development or Commercialization efforts for the Product in the Field in the Licensed Territory;
